Stock Information
Ligand Pharmaceuticals Inc (LGND)
Ticker Symbol: LGND
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $5,723.73 mil
Piotroski score: 4
PE Ratio: 30.29
EPS (TTM): 9.40
Revenue (TTM): $13.31 M
Dividend Yield: N/A
ROE: 20.06%
Latest News
-
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
Tue, Sep 29, 2026 4:25 AM
-
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution
Mon, Sep 28, 2026 11:20 AM
-
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
Sun, Sep 27, 2026 1:08 PM
-
IBM upgrade, SpaceX initiation among today's top calls on Wall Street
Fri, Sep 25, 2026 1:43 PM
-
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Fri, Sep 25, 2026 8:30 AM
-
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
Thu, Sep 24, 2026 11:54 AM
-
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Thu, Sep 24, 2026 11:00 AM
-
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Wed, Sep 23, 2026 11:13 AM
-
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Tue, Sep 22, 2026 1:02 PM
-
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Tue, Sep 22, 2026 1:00 PM
Key Financials
Financial data not available
